Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32689
Title: The assessment of severe cutaneous adverse drug reactions
Austin Authors: Copaescu, Ana M;Trubiano, Jason 
Affiliation: McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
Infectious Diseases
Issue Date: Apr-2022
Date: 2022
Publication information: Australian Prescriber 2022; 45(2)
Abstract: Severe cutaneous adverse drug reactions include Stevens-Johnson syndrome, toxic epidermal necrolysis and acute generalised exanthematous pustulosis. These eruptions are a type of delayed hypersensitivity reaction and can be life-threatening. The assessment of a severe cutaneous drug reaction requires a detailed clinical history and examination to identify the culprit drug and evaluate the allergy. Allopurinol, antibiotics and anticonvulsants are often implicated. Patch testing and delayed intradermal testing can assist in determining if the reaction was allergic, however there is limited evidence about the sensitivity and specificity of skin testing in severe cutaneous adverse drug reactions. If the testing is non-conclusive or negative, it is recommended to avoid the suspected culprit drug and any structurally similar drug in future. Any decision to reintroduce a drug should be made after considering the harm-benefit ratio. Caution is also needed if considering a possibly cross-reactive drug in a patient with a history of severe cutaneous adverse drug reactions.
URI: https://ahro.austin.org.au/austinjspui/handle/1/32689
DOI: 10.18773/austprescr.2022.010
ORCID: 0000-0002-9183-5032
0000-0002-5111-6367
Journal: Australian Prescriber
Type: Journal Article
Subjects: Stevens- Johnson syndrome
acute generalised exanthematous pustulosis
adverse drug reactions
delayed hypersensitivity
drug eruptions
Appears in Collections:Journal articles

Show full item record

Page view(s)

24
checked on Dec 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.